Sponsors (2)
The bill improves detection, provider/patient awareness, and access to TD treatments—potentially improving outcomes for people on antipsychotics—but could raise short‑term costs and risk unintended stigma or therapy avoidance if not implemented carefully.
People taking antipsychotics (and their clinicians and care partners) will receive more routine screening plus targeted education, leading to earlier detection of tardive dyskinesia (TD), better recognition of symptoms, and care more closely aligned with clinical guidance.
Patients diagnosed with TD will have greater access to FDA‑approved treatments for symptom management, which can improve quality of life for those affected.
More routine screening, education, and subsequent diagnoses will increase short‑term healthcare utilization and costs for providers, payers, and potentially taxpayers, and may raise out‑of‑pocket expenses for some patients if coverage is limited.
Greater emphasis on screening and diagnosing TD could inadvertently stigmatize people treated with antipsychotics or discourage needed antipsychotic use if not implemented with careful clinical context.
Based on analysis of 2 sections of legislative text.
Encourages education, awareness, and routine screening for tardive dyskinesia among people treated with antipsychotics to promote early detection and care aligned with best practices.
Introduced October 30, 2025 by Markwayne Mullin · Last progress October 30, 2025
Encourages increased education, awareness, and routine screening for tardive dyskinesia (TD) among people taking antipsychotic medicines, noting rising antipsychotic use, the large number of undiagnosed TD cases, and groups at higher risk. It urges clinicians, patients, and care partners to follow clinical best practices—such as regular TD screening and use of available FDA-approved treatments—so antipsychotic-treated patients receive timely detection and care. The text does not create new funding or mandates; it expresses interest in promoting clinician and patient education, aligning practice with American Psychiatric Association guidance, and raising awareness about TD risk factors and existing treatments.